The installation of a high potency facility marks the second phase of our expansion strategy. The expansion enables YProtech to […]
Professor Peter O’Brien and Dr Peter Karadakov, together with academic partner Professor Jacques Maddaluno (Rouen) and industrial partners AstraZeneca and […]
YProtech have secured a successful fundraise for specialist chemical technology services company arranged by Acceleris Capital. YProtech have raised £0.25m […]
YProtech has obtained Home Office approval under the Misuse of Drugs Act 1971 to Possess, Supply and Produce Controlled Drugs […]
YProtech are now offering the pyrrolobenzadiazapine cytotoxin natural products Tomaymycin (CAS 35050-55-6) and Tomaymycin DM (CAS 945490-09-5). Manufactured in the […]
Building on successful internal projects YProtech now offers multigram quantities of enzyme cleavable linker compounds for Antibody Drug Conjugates. Visit […]